Efficacy and cost effectiveness of lansoprazole versus omeprazole in maintenance treatment of symptomatic gastroesophageal reflux disease

American Journal of Managed Care

Volumn 5, Issue 7, 1999, Pages 881-886

  Vivian, Eva ^a   Morreale, Anthony ^b   Boyce, Eric ^a   Lowry, Kimberly ^b   Ereso, Oscar ^b   Hlavin, Patricia ^b  

^a UNIVERSITY OF THE SCIENCES   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; LANSOPRAZOLE; OMEPRAZOLE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CROSSOVER PROCEDURE; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROESOPHAGEAL REFLUX; HEADACHE; HEARTBURN; HUMAN; MAINTENANCE THERAPY; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; REFLUX ESOPHAGITIS; SINGLE BLIND PROCEDURE; SYMPTOM; THORAX PAIN;

EID: 0032783011     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Bell NJV, Hunt RH. Role of gastric acid suppression in the treatment of gastroesophageal reflux disease. Gut 1992; 33:118-124.
2. Robinson M, Sahba B, Avner D, et al. A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Aliment Pharmacol Ther 1995;9:25-31.
3. Ducrotte P, Guillemot F, Blanc LE, et al. Comparison of omeprazole and famotidine on esophageal pH in patients with moderate to severe esophagitis: A cross-over study. Am J Gastroenterol 1994;89:717-721.
4. Mee AS, Rowley JL. Rapid symptom relief in reflux oesophagitis: A comparison of lansoprazole and omeprazole. Aliment Pharmacol Ther 1996;10:757-763.
5. Takeda H, Hokari K, Asaka M. Evaluation of the effect of lansoprazole in suppressing acid secretion using 24 hour intragastric pH monitoring. J Clin Gastroenterol 1995;20(suppl 1):S7-S9.
6. Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995;333:1106-1110.
7. Castell DO, Richter JE, Robinson M, et al. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group. Am J Gastroenterol 1996:91:1749-1757.
8. Kitchin LI, Castell DO. Rationale and efficacy of conservative therapy for gastroesophageal reflux disease. Arch Intern Med 1991;151:448-454.
9. Richter JE, Castell DO. Drugs, foods and other substances in the cause and treatment of reflux esophagitis. Med Clin North Am 1981;65:1223-1234.
10. Festen HMP. Profound gastric acid inhibition, advantages and potential hazards. Scand J Gastroenterol 1989;171:99-105.
11. Joelson S, Joelson IB, Lundborg P, et al. Safety experience from long-term treatment with omeprazole. Digestion 1992:51(suppl 1):93-1-1.
12. Schindlbeck NE, Klauser AG, Voderholzer WA, et. al. Empiric therapy for gastroesophageal reflux disease. Arch Intern Med 1995;155:1808-1812.
13. Lepoutre L, Van Der Spek P, Vanderlinden I, et al. Combined therapy with cisapride and cimetidine in severe reflux oesophagitis. Hepatogastroenterology 1988;35:125-127.
14. Sontag SJ, Hirschowitz BI, Holt S, et al. Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: The U.S. multicenter study. Gastroenterology 1992;102:109-118.
15. Garnett WR. Efficacy, safety, and cost issues in managing patients with gastroesophageal reflux disease. Am J Hosp Pharm 1993;50(suppl 1):S11-S18.